Psithera Inc. completed a spin‑out from Roivant and closed a $47.5 million Series A financing while appointing Eric Shaff as president and CEO, the company disclosed in late 2025. The new entity refocused its pipeline on immune and inflammatory indications following separation from the Roivant umbrella. The cash injection funds early‑stage development and positioning ahead of IND‑enabling work. The financing illustrates continuing investor demand for immunology platforms spun out of larger venture‑backed stacks and signals renewed startup activity in specialty immunotherapeutics.